Form 8-K - Current report:
SEC Accession No. 0000950170-25-063969
Filing Date
2025-05-06
Accepted
2025-05-06 07:35:09
Documents
15
Period of Report
2025-05-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K okur-20250506.htm   iXBRL 8-K 48441
2 EX-99.1 okur-ex99_1.htm EX-99.1 155509
3 GRAPHIC img123771468_0.jpg GRAPHIC 18433
4 GRAPHIC img123771468_1.jpg GRAPHIC 18433
5 GRAPHIC img123771468_2.jpg GRAPHIC 18433
  Complete submission text file 0000950170-25-063969.txt   406853

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT okur-20250506.xsd EX-101.SCH 24879
17 EXTRACTED XBRL INSTANCE DOCUMENT okur-20250506_htm.xml XML 4720
Mailing Address 6707 WINCHESTER CIRCLE, SUITE 400 BOULDER CO 80301
Business Address 6707 WINCHESTER CIRCLE, SUITE 400 BOULDER CO 80301 (720) 307-2892
OnKure Therapeutics, Inc. (Filer) CIK: 0001637715 (see all company filings)

EIN.: 472309515 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40315 | Film No.: 25915260
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)